CD47 and neoplasm: While CD47 × PD‐L1 BisAb and standard anti‐PD‐L1 therapy inhibited tumor growth compared to isotype control (Figure 4b–d), the enhancement of myeloid populations within the spleen was only observed within the CD47 × PD‐L1 BisAb‐treated mice, whereas no changes were observed in the tumor (Supplementary figure 5a and b).